<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1410">
  <stage>Registered</stage>
  <submitdate>17/12/2006</submitdate>
  <approvaldate>17/12/2006</approvaldate>
  <nctid>NCT00412919</nctid>
  <trial_identification>
    <studytitle>Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma</studytitle>
    <scientifictitle>A Prospective, Single-Arm, 2-Stage, Open-label, Phase II Trial of Azacitidine in Relapsed and Refractory Multiple Myeloma.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AH213/06</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Azacitidine

Treatment: drugs: Azacitidine


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall response rate</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>time to progression</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>duration of response</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>number of cycles of azacitidine required to first achieve a response</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>progression free survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>safety</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>tolerability</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  diagnosis of MM as per IMWG criteria

          -  age greater than 17 years

          -  have received at least 2 but no more than 4 prior lines of therapy

          -  have failed to respond to the most recently administered anti-MM therapy or have
             demonstrably progressive disease as defined by accepted standard criteria

          -  have a life expectancy of at least 3 months

          -  ECOG performance status &lt; 3

          -  at registration haematological values within the following limits:

               1. absolute neutrophil count (ANC) &gt; 1.0 x 109/L

               2. platelet count &gt; 50 x 109/L unsupported

          -  At registration biochemical values within the following limits

               1. Bilirubin &lt; 1.5 x upper limit of normal (ULN) and transaminases &lt; 2 x ULN unless
                  considered secondary to hepatic myelomatous infiltration

               2. Serum creatinine &lt; 0.19mMol/L

          -  Written informed consent

          -  Must agree to use adequate contraceptive measures if indicated. Specifically, women of
             childbearing potential (WOCBP) may participate provided they meet the following
             conditions:

               1. Agree to use at least 2 effective contraceptive methods throughout the study and
                  for 30 days following the study

               2. Have a negative serum pregnancy test within 24 hours of commencing on study
                  medication

               3. Male participants with female partners that are WOCBP must agree to use 2
                  effective contraceptive methods throughout the study and for 30 days following
                  the study</inclusivecriteria>
    <inclusiveminage>17</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with monoclonal gammopathy of undetermined significance (MGUS) or
             indolent/smouldering MM

          -  Known or suspected hypersensitivity to AZA or mannitol

          -  Patients whose general condition makes them unsuitable for intensive treatment e.g.
             significant cardiac or pulmonary disease

          -  Active infections or other illnesses that precludes chemotherapy administration or
             patient compliance

          -  Active viral infection with known human immunodeficiency virus (HIV) or viral
             hepatitis type B or C

          -  Pregnant or lactating women</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>7</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Bayside Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase II trial evaluating the overall response rate, safety and tolerability to
      azacitidine in patients with relapsed or refractory multiple myeloma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00412919</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Spencer, Assoc. Prof</name>
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>